SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

14 Apr 2026 07:00

RNS Number : 2721A
Oxford Instruments PLC
14 April 2026
 

 

Oxford Instruments plc

Full-year trading update - 14 April 2026

 

Strong second half - full year in line with expectations

Continued strong order momentum in Advanced Technologies

Oxford Instruments plc ("Oxford Instruments" or "the Group"), a leading provider of scientific technology tools, software and expertise to academic and commercial partners, is today issuing a trading update for the year ended 31 March 2026 for continuing operations1.

We expect to deliver a resilient full-year performance in line with market expectations2. Full-year order intake for the Group is expected to be up c. 8% on an organic constant currency (OCC)3 basis versus prior year, with a book-to-bill ratio of c. 1.07.

After a tariff-disrupted start to the financial year, we have seen continued positive quarter-on-quarter order intake momentum in our Imaging & Analysis ("I&A") division. Following a return to growth in H2, full-year order intake is expected to be in line with the prior year on a reported basis, and marginally up versus prior year on an OCC basis.

Within our Advanced Technologies ("AT") division, tailwinds in the compound semiconductor market, and increasing traction with volume manufacturing customers, have driven c. 30% OCC year-on-year order growth. Order intake accelerated in H2, mainly driven by large US and European commercial customers. Following receipt of a significant multi-year order in April 2026, the current AT order book materially covers planned revenue for FY27, with orders now extending into FY28.

As anticipated, strong execution and improving market conditions in the second half delivered a Group revenue performance significantly ahead of H1, with H2 revenue marginally below the prior year on a reported basis, moving to slightly positive growth on an OCC basis.

Group operating profit margin continued to benefit from the cost restructuring actions undertaken at our Belfast-based imaging business, and from the expected margin improvement from H2 revenue growth.

The first £50m tranche of the share buyback programme was completed at the end of February. As at 31 March 2026, £11.7m of the second £50m tranche had been completed.

Richard Tyson, Chief Executive Officer, commented:

"The Group's strong execution in the second half, coupled with excellent order growth in Advanced Technologies, led to a resilient full-year performance against a challenging external backdrop; testament to the great work and agility of all of the team at Oxford Instruments. With good momentum and a strong order book we are well positioned for growth into the new financial year and beyond."

 

FY26 preliminary results

Oxford Instruments management will present its full-year results to analysts and investors at Deutsche Numis, 21 Moorfields, London, EC2Y 9DB on 9 June 2026.

Notes:

1. Excludes the NanoScience business and directly related costs which exited the Group upon final deal closing. All numbers unaudited and based on current expectations.

2. The mean of consensus estimates for reported full year FY26 results are for revenue of £420.7m, adjusted operating profit of £71.3m, and adjusted operating margin of 16.9%. Please refer to the Company website for more details of how consensus is calculated. Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non-recurring items, and the mark-to-market movement of financial derivatives

3. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme.

 

The financial information in this trading update is unaudited. LEI: 213800J364EZD6UCE231

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Director of Investor Relations 07776 433916

Stephen.lamacraft@oxinst.com

 

 

MHP Group

Katie Hunt/Tim Rowntree/ 07884 494112

Hugo Harris oxfordinstruments@mhpgroup.com

 

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with

market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKNBNABKDFQD
Date   Source Headline
12th Mar 202011:11 amPRNDirector/PDMR Shareholding
4th Mar 202010:02 amPRNAppointment of External Auditor
2nd Mar 202012:06 pmPRNTotal Voting Rights
2nd Mar 202012:02 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20207:00 amRNSDisposal of OI Healthcare business in the US
10th Feb 20201:49 pmPRNDirector/PDMR Shareholding
3rd Feb 202012:41 pmPRNTotal Voting Rights
29th Jan 20207:00 amRNSSale of Minority Share in Scienta Omicron
23rd Jan 202010:52 amPRNAdditional Listing
13th Jan 20209:55 amPRNDirector/PDMR Shareholding
10th Jan 202012:02 pmRNSPrice Monitoring Extension
9th Jan 202010:42 amPRNTotal Voting Rights
9th Jan 20209:41 amPRNBlocklisting - Interim Review
3rd Jan 20208:36 amPRNHolding(s) in Company
11th Dec 20194:03 pmPRNDirector/PDMR Shareholding
2nd Dec 20192:54 pmPRNTotal Voting Rights
12th Nov 201912:49 pmPRNDirector/PDMR Shareholding
12th Nov 20197:00 amRNSHalf-year Report
11th Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20194:34 pmPRNDirector/PDMR Shareholding
3rd Oct 201911:00 amPRNTotal Voting Rights
11th Sep 20193:30 pmPRNDirector/PDMR Shareholding
11th Sep 201912:12 pmPRNResult of AGM
11th Sep 201910:50 amPRNDirector/PDMR Shareholding
10th Sep 20197:00 amRNSChairman's AGM Statement 2019
29th Aug 201912:07 pmRNSSecond Price Monitoring Extn
29th Aug 201912:02 pmRNSPrice Monitoring Extension
22nd Aug 20191:24 pmPRNHolding(s) in Company
13th Aug 201910:26 amPRNDirector/PDMR Shareholding
15th Jul 20194:26 pmPRNDirector/PDMR Shareholding
11th Jul 201911:49 amPRNDirector/PDMR Shareholding
1st Jul 201911:07 amPRNBlocklisting - Interim Review
27th Jun 20195:01 pmPRNHolding(s) in Company
26th Jun 20195:30 pmRNSRPC Group
11th Jun 20191:02 pmPRNDirector/PDMR Shareholding
11th Jun 20197:00 amRNSFinal Results
30th May 20191:18 pmPRNHolding(s) in Company
13th May 201910:27 amPRNDirector/PDMR Shareholding
11th Apr 201912:00 pmPRNDirector/PDMR Shareholding
11th Apr 20197:00 amRNSTrading Statement
22nd Mar 20197:00 amRNSContract win
11th Mar 20191:40 pmPRNDirector/PDMR Shareholding
12th Feb 20191:32 pmPRNDirector/PDMR Shareholding
1st Feb 20199:56 amPRNDirector Declaration
15th Jan 201910:28 amPRNAdditional Listing
14th Jan 20194:01 pmPRNBlocklisting - Interim Review
11th Jan 201910:28 amPRNDirector/PDMR Shareholding
3rd Jan 201912:26 pmPRNDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.